Patient-Centric Design of the Lonapegsomatropin Auto-Injector for Growth Hormone Deficiency: Usability Validation of Safe and Effective Use.
The lonapegsomatropin Auto-Injector was successfully used by all participants in a simulated setting, indicating potential for improved adherence in pediatric growth hormone therapy.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This study evaluated the usability of the lonapegsomatropin Auto-Injector for pediatric growth hormone deficiency (pGHD). A total of 135 participants, including children, caregivers, and healthcare providers, were involved in simulated injection tasks. All participants successfully completed the injection with low rates of use deviations.
Abstract
<h4>Purpose</h4>Treatment of pediatric growth hormone deficiency (pGHD) with daily somatropin (human growth hormone [hGH]) injections is associated with challenges including needle anxiety, which may lead to poor adherence and ultimately result in suboptimal growth outcomes. The lonapegsomatropin (TransCon hGH, SKYTROFA<sup>®</sup>) Auto-Injector, designed to deliver once-weekly lonapegsomatropin for the treatment of pGHD while minimizing injection challenges, was validated in usability studies in pGHD.<h4>Patients and methods</h4>The Auto-Injector was evaluated in a usability validation study conducted under simulated-use conditions in accordance with FDA guidance, involving simulated injections performed by injection-naive or injection-experienced patients with pGHD or proxy medical conditions, caregivers, and health care providers (HCPs) responsible for injections or training patients/caregivers. Half of the patient and caregiver participants received training by a Nurse Trainer.<h4>Results</h4>All participants (60 children, 60 caregivers, and 15 HCPs) were able to complete an injection successfully. All participants reported that they could follow the instructions as written, and 98% felt they could use the device as intended on their own or, for pediatric patients, with supervision. Use deviations observed for injection tasks for all participant groups were low: patients (3.2% of tasks), caregivers (2.4%), and HCPs (2.8%).<h4>Conclusion</h4>The user-centric design of the lonapegsomatropin Auto-Injector enables successful and confident use to deliver an injection as intended, with the potential to overcome known barriers associated with GH injections and facilitate adherence, which may improve treatment outcomes.
Background
The paper addresses the usability of an auto-injector for Lonapegsomatropin, a growth hormone therapy. Prior knowledge indicates that ease of use is critical for patient adherence to growth hormone treatments. This study is significant as it aims to validate the design of a device intended to enhance patient experience and safety.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.